Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fospropofol - Eisai

Drug Profile

Fospropofol - Eisai

Alternative Names: Aquavan®; Fospropofol disodium; GPI 15715; HX0507; Lusedra; PQ 1002

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ProQuest Pharmaceuticals
  • Developer Eisai Co Ltd; West China Hospital Sichuan University; Yichang Humanwell Pharmaceutical
  • Class Anaesthetics; Hypnosedatives; Phenols; Small molecules
  • Mechanism of Action GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Sedation

Most Recent Events

  • 18 Feb 2021 No development reported - Phase-III for Sedation (In volunteers) in China (IV)
  • 12 Feb 2018 Yichang Humanwell Pharmaceutical in collaboration with West China Hospital, Sichuan University completed a phase III trial in Sedation (In volunteers) in China (ChiCTR1800016329)
  • 19 Jan 2018 Yichang Humanwell Pharmaceutical in collaboration with Sichuan University completes a phase III trial in Sedation (In volunteers) in China (ChiCTR1800016410)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top